Mocht u de informatie op onze website kanker-actueel.nl waarderen dan wilt u ons misschien ondersteunen met een donatie?

Ons rekeningnummer is: RABO 37.29.31.138 t.n.v. Stichting Gezondheid Actueel in Terneuzen. Onze IBANcode is NL79 RABO 0372 9311 38

Als donateur kunt u ook korting krijgen bij verschillende bedrijven. En we hebben een ANBI status

Zie ook in gerelateerde artiekelen.

6 september 2019:

Recent is een nieuwe reviewstudie gepubliceerd over het New Castle Disease Virus bij de behandeling van kanker. Auteurs prof. dr. Volker Schirrmacher *, Dr. Stefaan van Gool en Wilfried Stuecker , allen werkzaam in het IOZK - Keulen. Zij werken al jaren met het Newcastle Disease Virus.

Klik op de titel van de studie voor het studierapport in PDF vorm:

Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy

Hier het abstract maar het studierapport is zeer uitgebreid. Zeker de moeite waard dit te lezen.

Volker Schirrmacher *, Stefaan van Gool and Wilfried Stuecker Immune-Oncological Center Cologne (IOZK), D-50674 Cologne, Germany * Correspondence: V.Schirrmacher@web.de Received: 30 July 2019; Accepted: 23 August 2019; Published: 30 August 2019 Abstract: Resistance to therapy is a major obstacle to cancer treatment. It may exist from the beginning, or it may develop during therapy. The review focusses on oncolytic Newcastle disease virus (NDV) as a biological agent with potential to break therapy resistance. This avian virus combines, upon inoculation into non-permissive hosts such as human, 12 described anti-neoplastic effects with 11 described immune stimulatory properties. Fifty years of clinical application of NDV give witness to the high safety profile of this biological agent. In 2015, an important milestone was achieved, namely the successful production of NDV according to Good Manufacturing Practice (GMP). Based on this, IOZK in Cologne, Germany, obtained a GMP certificate for the production of a dendritic cell vaccine loaded with tumor antigens from a lysate of patient-derived tumor cells together with immunological danger signals from NDV for intracutaneous application. This update includes single case reports and retrospective analyses from patients treated at IOZK. The review also presents future perspectives, including the concept of in situ vaccination and the combination of NDV or other oncolytic viruses with checkpoint inhibitors.

16 mei 2017: Ik heb dit artikel uit 2003 en 2010 (!!!!!) eens naar voren gehaald omdat de resultaten van dendritische celtherapie met het Newcastle Disease virus bij mensen met vormen van darmkanker bijzonder aansprekend zijn:

Zo gaf de overleving van patienten die operabel waren deze verschillen te zien:

De 5, 6, 7 jaars overleving waren respectievelijk 66.51%, 60.52%. 56.50% voor de patienten uit de groep die na een operatie immuuntherapie kreeg met dendritiche celtherapie en NDV virus tegenover 45.57%, 44.76% en 43.42% respectievelijk in de grope die na operatie chemo en/of bestraling kreeg. De overleving steeg met de immuuntherapie met 20.94%, 15.76% en 13.08% respectievelijk op 5, 6 en 7 jaar. .

Table 5

Comparison of median survival period, mean survival period of resected colorectal cancer patients of vaccina-tion group and controlled group

Treatment method	n	Median survival period (year)	Mean survival period (year)
Resection plus vaccination group	310	> 7^a	5.13 ± 0.60^b
Resection alone group	257	4.46	4.15 ± 0.60

^bP < 0.01 vs resection alone group.

Hieronder de grafiek hoe de overleving per jaar verloopt:

Table 3

Comparison of yearly survival rates of resected colorectal cancer patients in vaccination group and controll group

Year	n	^aYearly survival rates (% ± s^-x)
Year	n	0	1	2	3	4	5
Vaccination group	310	97.05 ± 0.97	84.35 ± 2.10	76.42 ± 3.23	71.12 ± 3.43	66.51 ± 3.84	60.52 ± 4.57
Controll group	257	93.16 ± 1.60	74.83 ± 2.51	62.50 ± 2.06	50.58 ± 1.99	45.57 ± 1.32	44.76 ± 0.81

^aLife table χ² test P < 0.005 of the two groups.

Het volledige studieverslag: Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive traet is gratis in te zien inmiddels. Onderaan het abstract en referentielijst.

Update 23 januari 2010: bron: Pubmed

Chinese onderzoekers hebben in een gerandomiseerde studie bij kankerpatiënten met spijsverteringskanker bewezen dat een aanpak na operatie met dendritische cellen en het Newcastle virus significant langere overlevingstijd kan worden bereikt. Dit abstract werd in 2003 gepubliceerd. Hier kunt u het volledige studierapport lezen inclusief grafieken enz.
We hebben het abstract nu januari 2010 voor u vertaald met hulp van google:

Toepassing van autologe tumorcellen (dendritische cellen) en NDV - Newcastle Disease Virus vaccin in de behandeling van tumoren van het spijsverteringskanaal.

Liang W, Wang H, Sun TM, Yao WQ, Chen LL, Jin Y, Li CL, Meng FJ. Liaoning Provinciale Tumor Research Institute, 44 xiaoheYan Road, Dadong District, Shenyang 110042, Liaoning Province, China.

Doel: patiënten met spijsverteringskanker stadium I-IV, met kwaadaardige tumoren in het maagdarmkanaal werden met behulp van een vaccin van autologe tumorcellen (dendritische cellen) en het NDV (Newcastle disease virus) behandeld, en gevolgd en beoordeeld op ziektevrije tijd en een genezende werking.

METHODES: 335 patiënten met maligne tumoren van het maagdarmkanaal werden behandeld met een vaccin van autologe tumorcellen (dendritische celtherapie) en het NDV vaccin. Het autologe tumorcellen vaccin werd ingezet voor ziektevrije tijd en overall overleving op lange termijn. Hoewel vers autoloog tumor weefsel niet verkrijgbaar was werd het autologe vaccin gegeven samen met het NDV vaccin voor korte termijn effect op curatieve werking.

RESULTATEN: De darmkanker patiënten behandeld met het autologe tumorcel vaccin - dendritische cellen en werden verdeeld in twee groepen: de controle groep (onderworpen aan resectie - operatie alleen) (n = 257), een vaccin groep (onderworpen aan zowel de resectie en immunotherapie) (n = 310). 25 patiënten behandeld met immunotherapie plus NDV waren allemaal in fase IV stadium zonder resectie - operatie. In postoperatieve adjuvante therapie bij patiënten, was de 5, 6 en 7-jaars overleving respectievelijk 66,51%, 60,52% en 56,50%. Bij controlegroep van patiënten met alleen operatie, was de 5,6 en 7 -jaars overleving slechts 45,57%, 44,76% en 43,42% respectievelijk. De mediane ziektevrije periode was 5,13 jaar (resectie alleen groep 4,15 jaar), de mediane overleving periode was meer dan 7 jaar (voor groep met alleen resectie 4,46 jaar). Er waren significante verschillen tussen de twee groepen. Bij de patiënten die werden behandeld met resectie plus vaccin werden vertraagd-type overgevoeligheid (DTH) reacties gemeten na vaccinatie, (induratieve reikwijdte> 5 mm). De grootte van DTH was gerelateerd aan de prognose. De 5-jaarsoverleving was 80% voor degenen met indurations groter dan 5 mm, vergeleken met 30% voor degenen met indurations minder dan 5 mm. De 1-jaarsoverleving was 96% voor 25 patiënten behandeld met immunotherapie NDV. De totale effectieve cijfers (CR + PR) was 24,00% in NDV immunotherapie; complete remissie (CR) in 1 geval (4,00%), partiële remissie (PR) in 5 gevallen (20,00%), stabiele ziekte in 16 gevallen (64,00%) , progressie (PD) in 1 geval (4,00%). Na NDV vaccin immunotherapie was het aantal natuurlijke NK-cellen verhoogd en immuunfunctie sterk verbeterd.

CONCLUSIE: De autologe tumorcellen (dendritische cellen) en het NDV - New Castle Disease Virus kan het leven van darmkankerpatienten verlengen. Het NDV vaccin is met name effectief voor de korte termijn met de bevordering van de kwaliteit van leven en kan gebruikt worden indien nodig met goede vooruitzichten.

PMID: 12632504 [PubMed - indexed for MEDLINE].

The autologous tumor cell vaccine and NDV vaccine can prolong the patients’ life. NDV vaccine is notably effective for short-term with promotion of quality of life and can be used whenever necessary with good prospects.

Source:

. 2003 Mar 15; 9(3): 495–498.

Published online 2003 Mar 15. doi: 10.3748/wjg.v9.i3.495

Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract.
Liang W, Wang H, Sun TM, Yao WQ, Chen LL, Jin Y, Li CL, Meng FJ. Liaoning Provincal Tumor Research Institute, 44 xiaoheYan Road, Dadong District, Shenyang 110042, Liaoning Province, China.

AIM: To treat patients with stage I-IV malignant tumors of digestive tract using autologous tumor cell vaccine and NDV (Newcastle disease virus) vaccine, and observe the survival period and curative effect.
,br> METHODS: 335 patients with malignant tumors of digestive tract were treated with autologous tumor cell vaccine and NDV vaccine. The autologous tumor cell vaccine received were assigned for long-term survival observation. While these failed to obtain the autologous tumor tissue were given with NDV vaccine for a received short-term observation on curative effect.

RESULTS: The colorectal cancer patients treated with autologous tumor cell vaccine were divided into two groups: the controlled group (subjected to resection alone) (n=257), the vaccine group (subjected to both resection and immunotherapy) (n=310). 25 patients treated with NDV immunotherapy were all at stage IV without having resection. In postoperation adjuvant therapy patients, the 5, 6 and 7-year survival rates were 66.51 %, 60.52 %, 56.50 % respectively; whereas in patients with resection alone, only 45.57 %, 44.76 % and 43.42 % respectively. The average survival period was 5.13 years (resection alone group 4.15 years), the median survival period was over 7 years (resection alone group 4.46 years). There were significant differences between the two groups. The patients treated with resection plus vaccine were measured delayed-type hypersensitivity (DTH) reactions after vaccination, (indurative scope >5 mm). The magnitude of DTH was related to the prognosis. The 5-year survival rate was 80 % for those with indurations greater than 5 mm, compared with 30 % for those with indurations less than 5 mm. The 1-year survival rate was 96 % for 25 patients treated with NDV immunotherapy. The total effective rate (CR+PR) was 24.00 % in NDV immunotherapy; complete remission (CR) in 1 case (4.00 %), partial remission (PR) in 5 cases (20.00 %), stabilizedin in 16 cases (64.00 %), progression (PD) in 1 case (4.00 %). After NDV vaccine immunotherapy, the number of NK cell increased and immune function imporved obviously.

CONCLUSION: The autologous tumor cell vaccine and NDV vaccine can prolong the patients' life. NDV vaccine is notably effective for short-term with promotion of quality of life and can be used whenever necessary with good prospects.

PMID: 12632504 [PubMed - indexed for MEDLINE] .

References

1. Mimori K, Mori M. [Recent advances in the diagnosis and treatment of colorectal cancers] Nihon Geka Gakkai Zasshi. 2002;103:468–471. [PubMed]

2. Indar A, Maxwell-Armstrong CA, Durrant LG, Carmichael J, Scholefield JH. Current concepts in immunotherapy for the treatment of colorectal cancer. J R Coll Surg Edinb. 2002;47:458–474. [PubMed]

3. de Kleijn EM, Punt CJ. Biological therapy of colorectal cancer. Eur J Cancer. 2002;38:1016–1022. [PubMed]

4. Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Okouchi S, Isomoto H, et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res. 2001;7:3950–3962. [PubMed]

5. Bartnes K. [Tumor antigens presented to T helper lymphocytes--critical components of the cancer vaccine] Tidsskr Nor Laegeforen. 2001;121:2941–2945. [PubMed]

6. Zou SC, Qiu HS, Zhang CW, Tao HQ. A clinical and long-term follow-up study of peri-operative sequential triple therapy for gastric cancer. World J Gastroenterol. 2000;6:284–286. [PMC free article] [PubMed]

7. Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Møller M, Lindblom A, et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A. 2001;98:13255–13260. [PMC free article] [PubMed]

8. Harris JE, Ryan L, Hoover HC, Stuart RK, Oken MM, Benson AB, Mansour E, Haller DG, Manola J, Hanna MG. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol. 2000;18:148–157. [PubMed]

9. Zeh HJ, Stavely-O'Carroll K, Choti MA. Vaccines for colorectal cancer. Trends Mol Med. 2001;7:307–313. [PubMed]

10. Habal N, Gupta RK, Bilchik AJ, Yee R, Leopoldo Z, Ye W, Elashoff RM, Morton DL. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol. 2001;8:389–401. [PubMed]

11. Maxwell-Armstrong CA, Durrant LG, Buckley TJ, Scholefield JH, Robins RA, Fielding K, Monson JR, Guillou P, Calvert H, Carmichael J, et al. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer. 2001;84:1443–1446. [PMC free article] [PubMed]

12. Tartaglia J, Bonnet MC, Berinstein N, Barber B, Klein M, Moingeon P. Therapeutic vaccines against melanoma and colorectal cancer. Vaccine. 2001;19:2571–2575. [PubMed]

13. Safa MM, Foon KA. Adjuvant immunotherapy for melanoma and colorectal cancers. Semin Oncol. 2001;28:68–92. [PubMed]

14. Foon KA. Immunotherapy for colorectal cancer. Curr Oncol Rep. 2001;3:116–126. [PubMed]

15. Smith AM, Justin T, Michaeli D, Watson SA. Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer. Clin Cancer Res. 2000;6:4719–4724. [PubMed]

16. Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology. 2001;48:347–351. [PubMed]

17. Woodlock TJ, Sahasrabudhe DM, Marquis DM, Greene D, Pandya KJ, McCune CS. Active specific immunotherapy for metastatic colorectal carcinoma: phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha. J Immunother. 1999;22:251–259. [PubMed]

18. Suh KW, Piantadosi S, Yazdi HA, Pardoll DM, Brem H, Choti MA. Treatment of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte-macrophage colony-stimulating factor. J Surg Oncol. 1999;72:218–224. [PubMed]

19. Yamana H, Itoh K. [Specific immunotherapy with cancer vaccines] Gan To Kagaku Ryoho. 2000;27:1477–1488. [PubMed]

20. Chen W, Rains N, Young D, Stubbs RS. Dendritic cell-based cancer immunotherapy: potential for treatment of colorectal cancer. J Gastroenterol Hepatol. 2000;15:698–705. [PubMed]

21. Yip D, Strickland AH, Karapetis CS, Hawkins CA, Harper PG. Immunomodulation therapy in colorectal carcinoma. Cancer Treat Rev. 2000;26:169–190. [PubMed]

22. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O'Neil JD, Groene WS, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002;20:2251–2266. [PubMed]

23. Schneider T, Gerhards R, Kirches E, Firsching R. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol. 2001;53:39–46. [PubMed]

24. Schirrmacher V. [Anti-tumor vaccination] Zentralbl Chir. 2000;125 Suppl 1:33–36. [PubMed]

25. Zorn U, Duensing S, Langkopf F, Anastassiou G, Kirchner H, Hadam M, Knüver-Hopf J, Atzpodien J. Active specific immunotherapy of renal cell carcinoma: cellular and humoral immune responses. Cancer Biother Radiopharm. 1997;12:157–165. [PubMed]

26. Sonoda K, Sakaguchi M, Okamura H, Yokogawa K, Tokunaga E, Tokiyoshi S, Kawaguchi Y, Hirai K. Development of an effective polyvalent vaccine against both Marek's and Newcastle diseases based on recombinant Marek's disease virus type 1 in commercial chickens with maternal antibodies. J Virol. 2000;74:3217–3226. [PMC free article] [PubMed]

27. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther. 1999;6:63–73. [PubMed]

28. Csatary LK, Moss RW, Beuth J, Töröcsik B, Szeberenyi J, Bakacs T. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H) Anticancer Res. 1999;19:635–638. [PubMed]

29. Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC, Ansel JC, Gregersen PK, Armstrong CA. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med. 1998;4:783–794. [PMC free article] [PubMed]

30. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett. 2001;172:27–36. [PubMed]

31. Schirrmacher V, Griesbach A, Ahlert T. Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. Int J Oncol. 2001;18:945–952. [PubMed]

32. Zhang JK, Sun JL, Chen HB, Zeng Y, Qu YJ. Influence of granulocyte macrophage colony stimulating factor and tumor necrosis factor on anti-hepatoma activities of human dendritic cells. World J Gastroenterol. 2000;6:718–720. [PMC free article] [PubMed]

33. Termeer CC, Schirrmacher V, Bröcker EB, Becker JC. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther. 2000;7:316–323. [PubMed]

34. Schirrmacher V, Bai L, Umansky V, Yu L, Xing Y, Qian Z. Newcastle disease virus activates macrophages for anti-tumor activity. Int J Oncol. 2000;16:363–373. [PubMed]

35. Haas C, Ertel C, Gerhards R, Schirrmacher V. Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus. Int J Oncol. 1998;13:1105–1115. [PubMed]

36. King DJ. A comparison of the onset of protection induced by Newcastle disease virus strain B1 and a fowl poxvirus recombinant Newcastle disease vaccine to a viscerotropic velogenic Newcastle disease virus challenge. Avian Dis. 1999;43:745–755. [PubMed]

Articles from World Journal of Gastroenterology are provided here courtesy of Baishideng Publishing Group Inc

spijsverteringskanker, Newcastle Disease Virus, dendritische celtherapie, darmkanker